Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2022-12-03 Interim / Quarterly Rep…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and nine-month periods ended September 30, 2022. Since it provides comprehensive financial data for an interim period rather than just an announcement, it is classified as an Interim/Quarterly Report. 9M 2022
2022-12-03 English
FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022
Report Publication Announcement Classification · 1% confidence The document is a short notification (under 2,000 characters) from Enlivex Therapeutics Ltd to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 6K' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, and therefore qualifies as a Report Publication Announcement (RPA). FY 2022
2022-12-03 English
First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM
Regulatory Filings Classification · 1% confidence The document is a news release disseminated via EQS News, dated December 2, 2022, announcing that the first patients have been dosed in a Phase I/II clinical trial for a cell therapy candidate (AllocetraTM). It details the scientific background, the trial design (Phase I/II), and future expectations. This format—a timely announcement of a specific corporate/clinical event, often using boilerplate language about forward-looking statements and referencing SEC filings (like Form 20-F)—is characteristic of a general regulatory announcement or press release that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it is a specific corporate update that is not a formal financial report, dividend notice, or management change, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such announcements.
2022-12-02 English
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
Regulatory Filings Classification · 1% confidence The document is a news release disseminated via EQS News, dated December 1, 2022, announcing that the Israeli Ministry of Health cleared the way for human trials of AllocetraTM for solid tumors. It details the drug mechanism, the structure of the upcoming Phase I/II clinical trial, and includes standard forward-looking statements and contact information typical of a press release. This type of announcement, which releases key operational and clinical trial updates outside of mandated periodic financial reports (like 10-K or IR), fits best under the general category for regulatory announcements or news releases that don't fit a more specific financial category. Since it is a specific operational update rather than a general regulatory filing fallback (RNS), and it is not an Earnings Release (ER) or a formal Investor Presentation (IP), the most appropriate classification is Regulatory Filings (RNS) as a general news announcement, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is a clinical trial update. Given the options, RNS serves as the best fit for a non-financial, operational news announcement distributed broadly.
2022-12-01 English
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is a report of a Foreign Private Issuer, typically used to report material information that the company is required to disclose to its home country's regulators or stock exchange, or that it makes available to its shareholders. The content is a press release announcing that the FDA cleared an Investigational New Drug (IND) application for Allocetra™. This type of material, non-periodic disclosure by a foreign private issuer does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). Since it is a formal regulatory filing that doesn't match a more specific category, the most appropriate classification is the general regulatory filing fallback category, RNS (Regulatory Filings). The document length is substantial (8201 chars), indicating it is the primary document, not just an announcement of a report (RPA).
2022-11-28 English
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
Report Publication Announcement Classification · 1% confidence The document is very short (1771 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k28112022_DC_isa.pdf*". This structure—a brief announcement referencing an attached or linked primary document (in this case, a Form 6-K, which is an SEC filing for foreign private issuers)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notice of its publication. Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2022-11-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.